Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced that its management team will participate in a fireside chat and one-on-one meetings at Cantor's 2026 Global Healthcare Conference, scheduled for Sept. 9-11, 2026, in New York. President and CEO Seth Lederman, M.D., is set to present on Sept. 10 from 3:55-4:25 p.m. ET, with a live webcast and replay available through the Investors section of the Tonix website. This appearance underscores the company's ongoing efforts to engage with the investment community and communicate its strategic direction.
The announcement comes at a pivotal time for Tonix, which recently received approval for TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg), the first new treatment for fibromyalgia in over 15 years. This milestone marks a significant achievement for the company, positioning it as a commercial-stage biotechnology firm with a focus on central nervous system (CNS) and immunology treatments. The approval of TONMYA not only addresses a critical unmet medical need but also provides a foundation for future growth.
Tonix's CNS portfolio includes marketed products such as Zembrace SymTouch and Tosymra for acute migraine, which complement its commercial infrastructure. The company is also exploring the potential of TONMYA in Phase 2 clinical trials for major depressive disorder and acute stress disorder, indicating a broader application of its lead therapy. Additionally, Tonix is advancing TNX-2900, a Phase 2-ready candidate for Prader-Willi syndrome, a rare genetic disorder, highlighting its commitment to addressing underserved conditions.
Beyond CNS, Tonix is building a robust immunology pipeline. This includes TNX-4800, a monoclonal antibody for Lyme disease prophylaxis, and TNX-1500, a third-generation CD40 ligand inhibitor aimed at preventing kidney transplant rejection. These programs reflect the company's strategic diversification into areas with high unmet medical need, potentially expanding its market opportunities.
The participation in the Cantor conference provides Tonix with a platform to discuss these developments with investors and analysts. The fireside chat and one-on-one meetings offer an opportunity for management to articulate the company's vision, operational progress, and future milestones. For investors, this engagement is crucial in assessing the company's potential for long-term value creation.
Tonix's leadership in CNS and immunology, coupled with its recent commercial launch, positions the company for sustained growth. The ongoing clinical trials and pipeline advancements are expected to drive future catalysts. As the company continues to execute on its strategic plan, its presence at major healthcare conferences like Cantor's will be instrumental in maintaining investor confidence and attracting new stakeholders.
For more information about Tonix Pharmaceuticals and its pipeline, visit the company's newsroom at https://nnw.fm/TNXP.
